Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it presented preclinical...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Nature Communications has...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and...

WFC : 49.97 (+0.73%)
RGLS : 0.70 (-1.28%)
Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 50.00% and -99.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Cris Calsada...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Announces RGLS4326 Program Update

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a program update for RGLS4326...

RGLS : 0.70 (-1.28%)
Watch for Regulus Therapeu to Potentially Pullback After Gaining 7.86% Yesterday

Regulus Therapeu (NASDAQ:RGLS) traded in a range yesterday that spanned from a low of $1.51 to a high of $1.59. Yesterday, the shares gained 7.9%, which took the trading range above the 3-day high of...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of the first tranche...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Announces Restructuring of Term Loan

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has entered into an amendment...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Announces Private Placement of Equity

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has entered into a definitive...

RGLS : 0.70 (-1.28%)
Recent Analysis Shows Regulus Therapeutics, Limbach, CytRx, and Rand Capital Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regulus Therapeutics Inc. (NASDAQ:RGLS),...

LMBH : 15.6700 (+4.47%)
RGLS : 0.70 (-1.28%)
LMB : 4.87 (+1.67%)
CYTR : 0.2900 (-1.69%)
RAND : 2.65 (+7.64%)
Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress(TM) 2019

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present preclinical...

RGLS : 0.70 (-1.28%)
Regulus Therapeu Set to Possibly Rebound After Yesterday's Selloff of 1.97%

Regulus Therapeu (NASDAQ:RGLS) traded in a range yesterday that spanned from a low of $0.98 to a high of $1.01. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $1.00...

RGLS : 0.70 (-1.28%)
Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth...

RGLS : 0.70 (-1.28%)
Regulus Announces Transition of Research Leadership

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the resignation of Dr. Timothy...

RGLS : 0.70 (-1.28%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +4.48 , AIZ -0.27 , SBAC +4.06 , SO +0.08 , WELL +0.91
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar